{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:34:19Z","timestamp":1794566059713,"version":"4.9.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,24]],"date-time":"2027-06-24T00:00:00Z","timestamp":1813795200000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100009691","name":"Fondation pour la Recherche Nuovo-Soldati","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["CRP-17-111-01-CDD"],"award-info":[{"award-number":["CRP-17-111-01-CDD"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014269","name":"Philippe Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP256f0137008"],"award-info":[{"award-number":["JP256f0137008"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022184","name":"Institut Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022184","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100029173","name":"Merck Family Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100029173","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35CA220497"],"award-info":[{"award-number":["R35CA220497"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.annonc.2026.03.001","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:11:06Z","timestamp":1773457866000},"page":"946-959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7685-051X","authenticated-orcid":false,"given":"M.","family":"Aldea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3222-970X","authenticated-orcid":false,"given":"S.M.","family":"Lenahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-A.","family":"Locquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9572-4524","authenticated-orcid":false,"given":"L.","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gasparro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.C.","family":"Gokhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-R.","family":"Ghigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.N.","family":"Ionescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Odintsov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5511-2825","authenticated-orcid":false,"given":"K.","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-1105","authenticated-orcid":false,"given":"X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pecci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2394-9895","authenticated-orcid":false,"given":"E.","family":"Garbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-9396","authenticated-orcid":false,"given":"S.","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kulesza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3367-8426","authenticated-orcid":false,"given":"J.A.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1659-788X","authenticated-orcid":false,"given":"L.","family":"Zullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5366-2538","authenticated-orcid":false,"given":"M.","family":"Zielinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3966-1984","authenticated-orcid":false,"given":"A.","family":"Marinello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5617-6262","authenticated-orcid":false,"given":"G.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6073-6130","authenticated-orcid":false,"given":"G.","family":"Rossato de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7672-4035","authenticated-orcid":false,"given":"J.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Paoloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gariazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Santo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-875X","authenticated-orcid":false,"given":"J.","family":"Remon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8592-9892","authenticated-orcid":false,"given":"J.A.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"LoPiccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Florez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0275-0502","authenticated-orcid":false,"given":"M.","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ricciuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3606-827X","authenticated-orcid":false,"given":"J.","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Barbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Planchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-2960","authenticated-orcid":false,"given":"J.K.","family":"Rotow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-4148","authenticated-orcid":false,"given":"R.P.","family":"Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8976-5020","authenticated-orcid":false,"given":"W.W.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Paweletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6337-1093","authenticated-orcid":false,"given":"A.T.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7821-4928","authenticated-orcid":false,"given":"P.A.","family":"J\u00e4nne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6278","key":"10.1016\/j.annonc.2026.03.001_bib1","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"issue":"7283","key":"10.1016\/j.annonc.2026.03.001_bib2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"issue":"7793","key":"10.1016\/j.annonc.2026.03.001_bib3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes","volume":"578","author":"Aaltonen","year":"2020","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.annonc.2026.03.001_bib4","doi-asserted-by":"crossref","DOI":"10.1200\/PO-25-00564","article-title":"Clinical presentation of MTAP deletions in real-world settings: lessons for the clinical development of novel targeted therapies","volume":"9","author":"Best","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.03.001_bib5","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep"},{"issue":"11","key":"10.1016\/j.annonc.2026.03.001_bib6","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.annonc.2026.03.001_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1158\/2159-8290.CD-24-0887","article-title":"AMG 193, a clinical stage MTA-cooperative PRMT5 inhibitor, drives antitumor activity preclinically and in patients with MTAP-deleted cancers","volume":"15","author":"Belmontes","year":"2025","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.annonc.2026.03.001_bib8","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/acs.jmedchem.4c03067","article-title":"Discovery of TNG462: a highly potent and selective MTA-cooperative PRMT5 inhibitor to target cancers with MTAP deletion","volume":"68","author":"Cottrell","year":"2025","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.annonc.2026.03.001_bib9","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2026.03.001_bib10","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jtho.2025.09.054","article-title":"OA08.01 BMS-986504 in patients with homozygous MTAP-deletion (Del): clinical results in patients with NSCLC enrolled in CA240-0007","volume":"20","author":"Janne","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.03.001_bib11","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/cam4.4971","article-title":"Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency","volume":"12","author":"Ashok Kumar","year":"2023","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.annonc.2026.03.001_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104535","article-title":"Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data","volume":"10","author":"Ikushima","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.annonc.2026.03.001_bib13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jtho.2025.08.014","article-title":"MTAP expression by immunohistochemistry: a novel biomarker in non-small cell cancer of the lung","volume":"21","author":"Brune","year":"2026","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.03.001_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2024.103936","article-title":"1691 A complementary role for immunohistochemistry and NGS for detection of MTAP gene deletion in patients with non-small cell lung cancer","volume":"105","author":"Ilonen","year":"2025","journal-title":"Lab Invest"},{"issue":"10","key":"10.1016\/j.annonc.2026.03.001_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105807","article-title":"COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib","volume":"10","author":"Peled","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.annonc.2026.03.001_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2026.03.001_bib17","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2025.04.003","article-title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and\/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","volume":"36","author":"de Marinis","year":"2025","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.03.001_bib18","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1556-0864(25)00196-0","article-title":"1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD","volume":"20","author":"Le","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2026.03.001_bib19","doi-asserted-by":"crossref","first-page":"522","DOI":"10.6004\/jnccn.2025.7071","article-title":"Efficacy and safety of continuing next-generation ALK TKIs with chemotherapy for advanced ALK-positive NSCLC: a multicenter retrospective study","volume":"23","author":"Waliany","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.annonc.2026.03.001_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264138","article-title":"Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors","volume":"17","author":"Milbury","year":"2022","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.annonc.2026.03.001_bib21","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.annonc.2026.03.001_bib22","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","article-title":"Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer","volume":"141","author":"Garcia","year":"2017","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.annonc.2026.03.001_bib23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13059-024-03294-8","article-title":"Evaluation of somatic copy number variation detection by NGS technologies and bioinformatics tools on a hyper-diploid cancer genome","volume":"25","author":"Masood","year":"2024","journal-title":"Genome Biol"},{"key":"10.1016\/j.annonc.2026.03.001_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2024.100221","article-title":"Liquid biopsy detection of gene Copy Number (CN) losses including existing and emerging clinical targets","volume":"5","author":"Rolfo","year":"2024","journal-title":"J Liq Biopsy"},{"issue":"5","key":"10.1016\/j.annonc.2026.03.001_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.9286","article-title":"Response- and progression-based end points in trial and observational cohorts of patients with NSCLC","volume":"7","author":"Lu","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.annonc.2026.03.001_bib26","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/1475-6773.13669","article-title":"Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States","volume":"56","author":"Zhang","year":"2021","journal-title":"Health Serv Res"},{"issue":"1","key":"10.1016\/j.annonc.2026.03.001_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13402-010-0004-6","article-title":"Establishment and characterization of six human lung cancer cell lines: EGFR, p53 gene mutations and expressions of drug sensitivity genes","volume":"34","author":"Ku","year":"2011","journal-title":"Cell Oncol (Dordr)"},{"issue":"23","key":"10.1016\/j.annonc.2026.03.001_bib28","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1158\/1078-0432.CCR-18-0876","article-title":"Amplification of wild-type KRAS imparts resistance to crizotinib in MET Exon 14 mutant non-small cell lung cancer","volume":"24","author":"Bahcall","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.annonc.2026.03.001_bib29","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1158\/1078-0432.CCR-19-1844","article-title":"Use of ex vivo patient-derived tumor organotypic spheroids to identify combination therapies for HER2 mutant non-small cell lung cancer","volume":"26","author":"Ivanova","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.annonc.2026.03.001_bib30","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"issue":"6","key":"10.1016\/j.annonc.2026.03.001_bib31","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.03.001_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.1265","article-title":"1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)","volume":"35","author":"Solomon","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.03.001_bib34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jtho.2023.08.007","article-title":"Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged NSCLC","volume":"19","author":"Lara-Mej\u00eda","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.03.001_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.11.010","article-title":"Clinical significance of MTAP deletions and their overlap with concurrent oncogenic driver alterations including EGFR in non-small cell lung cancer","volume":"21","author":"Ross","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"18","key":"10.1016\/j.annonc.2026.03.001_bib36","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1158\/0008-5472.CAN-25-1464","article-title":"CRISPR-drug combinatorial screening identifies effective combination treatments for MTAP-deleted cancer","volume":"85","author":"Knoll","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.03.001_bib37","article-title":"Prevalence and actionability of MTAP loss in oncogene-driven lung cancer [Internet]. bioRxivorg","author":"Sakai","year":"2026","journal-title":"bioRxiv"},{"issue":"18","key":"10.1016\/j.annonc.2026.03.001_bib38","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-25-1507","article-title":"Combination of the MTA-cooperative PRMT5 inhibitor BMS-986504 and KRAS inhibitors is an effective treatment strategy for MTAP-deleted KRAS-mutant pancreatic cancer","volume":"85","author":"Drizyte-Miller","year":"2025","journal-title":"Cancer Res"},{"issue":"8 Suppl 1","key":"10.1016\/j.annonc.2026.03.001_bib39","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1158\/1538-7445.AM2025-2996","article-title":"Abstract 2996: TNG462, an MTA-cooperative PRMT5 inhibitor, demonstrates strong efficacy in combination with clinically relevant targeted therapies in MTAP-null preclinical models","volume":"85","author":"Zhang","year":"2025","journal-title":"Cancer Res"},{"issue":"609","key":"10.1016\/j.annonc.2026.03.001_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3738","article-title":"Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR -mutant lung cancer","volume":"13","author":"Eser","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.annonc.2026.03.001_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.108040","article-title":"The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations","volume":"199","author":"Patil","year":"2025","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2026.03.001_bib42","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","article-title":"Overcoming resistance to tumor-targeted and immune-targeted therapies","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer Discov"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426000992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426000992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:45:32Z","timestamp":1782315932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426000992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0923753426000992"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.03.001","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}